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Abstract
Background. Solid dispersions are among the techniques successfully employed to enhance the dissolu-
tion of poorly water-soluble drugs. Microwave (MW)-assisted evaporative crystallization has been used to 
prepare solid dispersions of drugs and polymers.
Objectives. The aim of the study was to investigate the solubility of apremilast (APM) in water by explo-
ring the effect of MW-assisted solid dispersion technology.
Material and methods. In the present study, solid dispersions of  APM, a  poorly water-soluble drug, 
were prepared. The solid dispersions were prepared using the conventional method (CM) and the MW-ba-
sed solvent evaporation technique. Microwave energy was used to enhance the solubility and dissolution 
rate of APM. The physical mixture and solid dispersions were characterized using Fourier-transform infrared 
spectroscopy (FTIR), X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and scan-
ning electron microscopy (SEM). Apremilast tablets containing MW-assisted solid dispersions were pre-
pared by the direct compression technique and compared with the marketed formulation (Aprezo tablets).
Results. The results obtained confirmed the conversion of  crystalline APM to an amorphous form. 
The XRPD pattern of the MW-assisted formulation at a 2:1 ratio suggests the amorphous structure of APM 
within the formulation. Based on solubility studies results, Syloid® 244FP was selected as the best carrier. 
The dissolution study results suggested that the APM tablet prepared using MW-assisted solid dispersions 
at a 2:1 carrier/drug ratio improved the APM dissolution rate compared to the marketed formulation.
Conclusions. Based on the results, it can be concluded that the MW-assisted solid dispersion technique 
may be an effective approach to enhancing the dissolution profile of other poorly water-soluble drugs.
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Introduction 
A drug being developed into an oral formulation re-
quires sufficient solubility in the dissolution medium in 
order to obtain optimal dissolution rates. The Biophar-
maceutics Classification System (BCS) recognizes the im-
portance of the rate of dissolution and aqueous solubility 
as key factors in the determination of the oral absorption 
of drugs.
Solid dispersions are among the techniques successfully 
employed to enhance the dissolution of  poorly water-
soluble drugs.1–9 Traditionally, solid dispersions are pre-
pared by the melting, melting-solvent or solvent methods. 
Newer methods for the manufacture of solid dispersions 
include hot spin mixing,10 supercritical fluid technology 
and hot-melt extrusion (HME).11,12 Researchers are also 
investigating the potential of  microwaves (MWs) to en-
hance solubility and bioavailability of poorly soluble drugs 
using the formation of  solid dispersions and nanocom-
posite materials. In a recent study, MW-assisted evapora-
tive crystallization was used to prepare solid dispersions 
of drugs and polymers.13
Microwaves are part of  the electromagnetic spectrum, 
the frequency range of which is 0.3–300 GHz. The migra-
tion of MW within materials causes molecular oscillation, 
which leads to the generation of  heat.14,15 The MW ap-
proach to heating is different from conventional heating, in 
which heat transfer takes place from the surface to the in-
ner core. In the MW approach, heat is generated in the ma-
terial and then passes to the entire volume, with a constant 
heating rate leading to uniform and deep heating of materi-
als.14,16 Microwave technology is rapid, cost-effective, ener-
gy-saving, and environmentally safe. The crystalline drug is 
generally converted into an amorphous form, which means 
the approach can be used for the improvement of the dis-
solution profiles of BCS class II and IV drugs.14,17
Apremilast (APM) is a  novel, orally available small 
molecule inhibitor of  type 4 cyclic nucleotide phospho-
diesterase (PDE4). It is indicated in the treatment of ac-
tive psoriatic arthritis in adults and moderate to severe 
plaque psoriasis.18–21 It is practically insoluble in aqueous 
buffers, irrespective of pH range; it is soluble in acetone, 
acetonitrile, methyl ethyl ketone, methylene chloride, and 
tetrahydrofuran. The BCS classifies APM as having low 
solubility and low permeability (i.e., BCS class 4). Very 
poor solubility of  APM in water influences the dissolu-
tion of the drug in aqueous media. Its oral bioavailability 
has been reported to be 20–33%.22,23 In order to achieve 
an acceptable dissolution profile, crystal forms of APM or 
reduction of the APM particle size have been studied to 
improve its dissolution.24,25
Considering the various attempts at improving solu-
bility of  APM with different approaches, the objective 
of present study was to increase the solubility of APM in 
water by exploring the effect of MW-assisted solid disper-
sion technology.
Materials and methods 
Apremilast was provided for the study by Glenmark 
Pharmaceuticals Ltd. (Nashik, India); APM tablets (Apre-
zo, the reference tablet) were purchased from the same 
company. Syloid® 244FP and Syloid® XDP 3150 were 
purchased from Grace GmbH & Co. KG (Worms, Ger-
many). Polyethylene glycol (PEG) 6000, polyvinylpyrrol-
idone (PVP), β-cyclodextrin, lactose monohydrate, ethyl 
cellulose, and magnesium stearate were obtained from 
Research Lab Fine Chem Industries (Mumbai, India). Ida-
col Erythrosine Food Red-4 coloring agent was obtained 
from Roha Dyechem Pvt. Ltd. (Mumbai, India). All other 
reagents were of analytical grade.
Determination of apremilast solubility  
in various buffers 
Saturation solubility studies of  APM in water, pH  1.2 
acidic buffer, pH 2, pH 4, pH 6.8, and pH 7.4 phosphate 
buffers, as well as pH 6.8 phosphate buffer with 0.15% so-
dium laureth sulfate (SLS) were conducted, using a mag-
netic stirrer (REMI Instruments Ltd., Mumbai, India). All 
media were prepared in individual flasks, and an excess 
amount of APM (≈50 mg) was weighed and transferred 
into the flasks. The flasks were placed on a magnetic stir-
rer at a  speed of  200  rpm for 24  h at 37°C. After 24  h, 
the solution was centrifuged at 2000 rpm for 15 min. The 
supernatants were diluted with the respective media. 
Absorbance was measured at 230 nm using a Shimadzu 
V-630UV Visible Spectrophotometer (Shimadzu Corp., 
Kyoto, Japan) and solubility was calculated.6,26
Preparation of physical mixtures  
of carriers and apremilast 
Apremilast and carriers (Syloid® 244FP (S244), Syloid® 
XDP 3150 (S3150), PEG 6000, PVP, and β-cyclodextrin) 
were each passed through a  No.  100 sieve and physical 
mixtures (PMs) were prepared by mixing pre-weighed 
amounts of APM with each carrier at a 1:1 ratio.
Preliminary trials for the preparation of solid 
dispersions by the conventional method 
We prepared solid dispersions of APM with the 5 selected 
carriers – S244, S3150, PEG 6000, PVP, and β-cyclodextrin 
− at a carrier/drug ratio of 1:1. The solid dispersions of APM 
with S244, S3150 and β-cyclodextrin were prepared using 
the solvent evaporation method: APM (250  mg) was dis-
solved in 3 mL of ethanol; after complete dissolution, the 
solution was transferred into a  round-bottom flask with 
a polymer carrier. The solvent was evaporated at 45°C and 
dried in a Hei-VAP Value HB/G5 rotary evaporator (Heido-
lph Instruments GmbH & CO. KG, Schwabach, Germany) 
for 2 h, and the residues were passed through a No. 85 sieve.
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To prepare solid dispersions of APM in PEG 6000 and 
PVP, APM (250 mg) was dissolved in 3 mL of ethanol; af-
ter complete dissolution, the solutions were transferred 
to beakers holding the polymeric carriers PEG 6000 and 
PVP. The solvent was evaporated at 45°C and the resulting 
residues were dried in a hot air oven for 1 h and stored in 
a  desiccator. Subsequently, the residues were ground in 
a mortar and passed through a No. 85 sieve. 
On the basis of  solubility studies, solid dispersions 
of APM with S244 at ratios of 2:1 and 3:1 were also pre-
pared. All the solid dispersions were stored in vials at 
room temperature until further use. These batches were 
identified with the symbol CM.27,28
The preparation of solid dispersions 
by the microwave-assisted solvent 
evaporation method 
For the microwaving process, we used a CATA 2R MW 
oven (Catalyst Systems, Pune, India), containing an in-
built mode stirrer to ensure even MW distribution. Ac-
curately weighed 0.5 g amounts of physically mixed S244 
with APM at ratios of 1:1, 2:1 and 3:1 were dissolved in 
3 mL of ethanol. After complete dissolution, the solutions 
were transferred to silica crucibles. The crucibles were 
kept in a MW oven at 560 W for 3 min, until the solvent 
completely evaporated.13,29,30 The prepared solid disper-
sions were passed through a No. 85 sieve and stored in 
vials at room temperature until further use. These formu-
lations were identified with the symbol MW.
Characterization of the solid dispersions 
Drug content 
The drug content of all the prepared solid dispersions 
was calculated. For each solid dispersion, an accurately 
weighed amount of  solid dispersion containing 30  mg 
of APM was transferred to a 100 mL volumetric flask, di-
luted to 100 mL with methanol and sonicated for 30 min 
for complete solubilization of the drug. The mixture was 
filtered using Whatman grade 41 filter paper and the ab-
sorbance was measured at 230 nm. The drug content was 
calculated using a Shimadzu V-1800 UV spectrophotom-
eter (Shimadzu Corp., Kyoto, Japan).14,25
Phase solubility studies 
The phase solubility studies were performed accord-
ing to the method described by Higuchi and Connors.31 
Physical mixtures and solid dispersions containing dif-
ferent carrier/APM ratios were prepared and added to 
glass vials containing 10  mL each of  different media. 
Each vial was shaken in a mechanical shaker for 12 h to 
obtain equilibrium solubility, and the solution was al-
lowed to equilibrate for 24 h. Each solution was further 
centrifuged at 2000  rpm for 10  min in an ultra-centri-
fuge and filtered through Whatman grade 41 filter paper. 
An aliquot was suitably diluted with distilled water and 
analyzed using the Shimadzu V-1800  UV spectropho-
tometer at 230 nm.32
Fourier-transform infrared study 
The Fourier-transform infrared spectra (FTIR) of APM, 
the PM of APM with S244 and solid dispersion (Batch 7, 
MW 2:1) were recorded over a range of 4000–400 cm−1 
to study the principal peaks with an Affinity-1 FTIR spectro-
photometer (Shimadzu Corp.) using the potassiumbromide 
(KBr) disc method.
X-ray powder diffraction analysis of apremilast 
The X-ray powder diffraction (XRPD) spectra of APM, 
S244, the PM of APM with S244 and all the solid disper-
sions were recorded using a Smart Lab high power powder 
X-ray diffractometer (Rigaku Corp., Tokyo, Japan) with 
Cu as a target filter, a voltage/current of 40 kV/40 mA and 
a scan speed of 4°/min. The samples were analyzed at a 2θ 
angle range from 10° to 89°. The step time was 0.5 s and 
the acquisition time was 1 h.33,34
Differential scanning calorimetry analysis 
Thermograms of  APM, S244, the PM of  APM with 
S244 and all the solid dispersions were recorded by using 
a  Shimadzu DSC-60 differential scanning calorimeter 
(Shimadzu Corp.). An empty aluminum pan was used 
as a  reference. The differential scanning calorimetry 
(DSC) measurements were performed at a heating rate 
of 10°C/min from 30°C to 300°C.29,35
Surface morphology 
The surface morphology of APM, the PM of APM with 
S244 and solid dispersion (Batch 7, MW 2:1) was stud-
ied using a Supra 5 scanning electron microscope (SEM) 
(Carl Zeiss AG, Oberkochen, Germany) with an acceler-
ating voltage of 10 kV.
Preparation of apremilast tablets  
using the direct compression technique 
All the ingredients as shown in Table 1 were individu-
ally passed through a No. 60 sieve. A solid dispersion con-
taining 30 mg of APM and microcrystalline cellulose were 
mixed to obtain a uniform mixture. The other ingredients 
were weighed, mixed and tablets were pressed using an 
11  mm concave round punch on a  Rimek compression 
machine (Karnavati Engineering Ltd., Ahmedabad, In-
dia). The post-compression parameters of  the uncoated 
tablets were evaluated before they were coated.36
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Preparation of coating solution for film coating 
Ethyl cellulose (1% w/w) was weighed accurately and 
added to approx. 5 mL of acetone in a beaker with contin-
uous stirring using the handshake method. Idacol Eryth-
rosine Food Red-4 coloring agent (Roha Dyechem Pvt. 
Ltd., Mumbai, India) was then added. The stirring was 
continued for 15 min.
Film coating of tablets 
The compressed tablets were coated in a conventional 
coating pan (Avon Engineering Work, Mumbai, India) 
with an inlet air temperature of  50–55°C, a  tablet bed 
temperature of  35–40°C and exhaust air temperature 
of 35–42°C. The pan speed, spray air pressure and solu-
tion spray rate were 25–30 rpm, 3 kg/cm2 and 20 mL/min, 
respectively. The tablets were dried for 15  min at 45°C. 
The coating increased weight of the core tablets by 4%.
Dissolution studies 
The dissolution rates of  the APM tablets and Aprezo 
(the reference tablet) were studied using a USP XXIII Dis-
solution Test Apparatus (Labindia Instruments, Mumbai, 
India) at 50 rpm in 900 mL of phosphate buffer (pH 6.8) 
with 0.15% SLS. The temperature of the dissolution me-
dium was maintained at 37 ±0.5°C. Aliquots (5 mL) were 
withdrawn at 5-, 10-, 20-, 30-, 40-, 50-, and 60-minute in-
tervals and filtered. The absorbance of the filtered sample 
solution was measured using the Shimadzu V-1800  UV 
spectrophotometer at 230 nm, and concentration of APM 
was determined from the standard calibration curve.
Results and discussion 
Solubility studies 
Our study showed that APM has poor solubility in all 
buffers. The highest solubility (24.74 ±0.857 µg/mL) was 
observed in phosphate buffer (pH  6.8) with 0.15% SLS 
(Table 2). The FDA has also suggested phosphate buffer 
(pH 6.8) with 0.15% SLS as a dissolution medium for APM 
tablets.37
All the carriers used in the preliminary trials showed 
an increase in the solubility of APM in both PMs and sol-
id dispersions (Tables  3 and  4). Several studies on solid 
dispersions have been published, confirming the advan-
tageous properties of solid dispersions in increasing the 
solubility and dissolution rate of  poorly water-soluble 
drugs. Solid dispersions tend to reduce particle size, pos-
sibly to a molecular level, and change the crystalline state 
of  drugs, thereby promoting their solubility.38,39 The re-
sults of phase solubility studies indicate that the solubil-
ity of APM was maximally enhanced when S244 was used 
as the carrier for preparing solid dispersions utilizing the 
conventional method (CM). This is because the increase 
in surface area, along with the potential existence of the 
drug in pores in an amorphous (rather than crystalline) 
form, can aid in enhancing solubility. When MW heating 
is used for solvent evaporation, a 3 mL solution complete-
ly evaporates within 3 min. Thus, the time consumed by 
MW-assisted solvent evaporation was significantly short-
er than in the conventional method. 
Further, when a  solid dispersion is prepared using the 
MW-assisted solvent evaporation method, it is possible 
that APM molecules are transported into the pores by cap-
illary action and stored in the pores in a partially crystalline 
and partially amorphous form. Earlier findings suggest that 
particle size decreased to the submicron range when using 
the MW-assisted technique, thus improving dissolution 
rate.13 However, at a  low carrier/drug ratio (1:1), surface 
adsorption of APM was noted. These results were also sup-
ported by the DSC thermogram. When the carrier/drug 
ratio is increased to 2:1, APM is more confined to the pores 
and can exist in an amorphous or a semi-crystalline state. 
Table 1. Composition of apremilast (APM) tablets prepared by direct 
compression method
Ingredients mg/tablet 
S244 + APM MW (2:1) 90.00
Lactose monohydrate 140.00 
Croscarmellose sodium 16.30 
Microcrystalline cellulose 41.50 
Magnesium stearate 2.20 
Total weight 290.00 
Table 3. Results of phase solubility studies of physical mixtures (PMs)
Physical mixtures Solubility  [µg/mL]
S244 + APM (1:1) 28 ±0.221
Syloid XDP 3150 + APM (1:1) 22 ±0.123
PVP + APM (1:1) 18 ±0.344
PEG 6000 + APM (1:1) 19 ±0.243
β-cyclodextrin + APM (1:1)  20 ±0.354
Data presents mean ± standard deviation (SD), n = 3.
Table 2. Results of solubility study of apremilast (APM) in different media 
Dissolution media Solubility  [µg/mL]
Water 5.4 ±0.298
pH 1.2, acidic buffer 5.2 ±0.118
pH 2, phosphate buffer 9.96 ±0.827
pH 4, phosphate buffer 14.96 ±1.065
pH 6.8, phosphate buffer 16.22 ±0.640
pH 6.8, phosphate buffer with 0.15% SLS 24.74 ±0.857
pH 7.4, phosphate buffer 22.84 ±0.331
Data presents mean ± standard deviation (SD), n = 3.
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A similar reduction in crystallinity was observed as the car-
rier/drug ratio is increased to 3:1. 
On the basis of our solubility studies, S244 was selected 
as the best carrier for the further studies.
Fourier-transform infrared study 
The FTIR spectrum of APM (Fig. 1) shows the charac-
teristic strong N–H stretching peak for APM at 3364 cm−1. 
The FTIR spectrum of APM also shows the characteristic 
peak at 1764 cm−1 due to amide carbonyl (C=O), along with 
the peaks between 2837 cm−1 and 3081 cm−1 for aliphatic 
and aromatic benzene ring C–H stretching. The peak for 
amide N–H bending was observed at 1597 cm−1 and the 
peak for C–O stretching was observed at 1164 cm−1. The 
FTIR spectrum of S244 showed a stronger intensity band 
from 900 cm−1 to 1300 cm−1 due to Si–O stretching of the 
silanol group. The FTIR spectra for the PM of APM with 
S244 and for solid dispersion (Batch 7, MW 2:1) show the 
combined individual characteristic peaks for APM and 
S244. The individual peaks for APM are more intense in 
the PM as compared to the solid dispersion. This suggests 
that in the PM, the physical interaction of APM with S244 
is weak; possibly APM is only physically interacting with 
the outer surface of the silica particles. In the solid disper-
sion, the individual peaks for APM are weak, which sug-
gests that MW irradiation results in pronounced physical 
interaction between APM at the deeper sites of the S244 
pores. The FTIR spectrum also clearly suggests that in 
both the PM and the solid dispersion, APM was physi-
cally adsorbed rather than undergoing any chemical inter-
action on the surface of the porous silica particles of S244.
Differential scanning calorimetry  
and X-ray diffraction 
Differential scanning calorimetry and XRPD were em-
ployed to investigate the crystal lattice of pure APM and 
APM solid dispersions with S244. Figure  2 depicts the 
DSC thermograms for S244, a PM of APM and S244, solid 
dispersions of S244 and APM obtained using the CM and 
the MW-assisted solvent evaporation method. Apremi-
last was characterized by a single sharp melting endother-
mic peak at 157.56°C. The peak onset temperature and 
heat of fusion (ΔHf) were 155.01°C and 111.0595 Jg−1, re-
spectively. This characteristic peak appeared in the PMs 
and in the CM batches at carrier/drug ratios of both 1:1 
and 2:1, with slight variations in terms of the melting peak 
depression and broadening, indicating the transition from 
Table 4. Results of drug content and solubility studies of solid dispersion 
Batch code Solid dispersion Drug content  [%]
Solubility  
[µg/mL]
APM 1 S244 + APM (CM 1:1) 97.24 ±3.24 28 ±0.154
APM 2 Syloid XDP 3150 + APM (CM 1:1) 96.88 ±2.84 23 ±0.231
APM 3 PVP+ APM (CM 1:1) 99.12 ±5.31 24 ±0.269
APM 4 PEG 6000 + APM (CM 1:1) 97.37 ±2.57 23 ±0.347
APM 5 β-cyclodextrin + APM (CM 1:1) 96.56 ±3.62 21 ±0.215
APM 6 S244 + APM (MW 1:1) 98.23 ±3.64 30 ±0.364
APM 7 S244 + APM (MW 2:1) 100.32 ±2.81 33 ±0.385
APM 8 S244 + APM (MW 3:1) 98.41 ±4.11 33 ±0.316
Data presents mean ± standard deviation (SD), n = 3
Fig. 1. Fourier transform infrared (FTIR) spectra of solid dispersion (MW 2:1), the 
physical mixture (PM) of S244 and apremilast (APM), S244 alone and APM alone
Fig. 2. Differential scanning calorimetry (DSC) thermograms of apremilast 
(APM), S244, the physical mixture (PM) of S244 and APM, solid dispersion 
(CM 1:1, CM 2:1), solid dispersion (MW 1:1, MW 2:1, and MW 3:1)
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a crystalline to a semi-crystalline state. In the MW solid 
dispersion of APM with S244 at a carrier/drug ratio of 1:1, 
a melting peak of less intensity was detected. At this ratio, 
the pore volume of S244 was insufficient for hosting extra 
APM molecules, and the residual APM instead remained 
on the external surface of  S244. However, the melting 
peak was completely absent in the 2:1 and 3:1 MW sol-
id dispersions, confirming the amorphous state of APM 
within these formulations.
Figure 3 displays the XRPD patterns of APM, S244 and 
the MW solid dispersions with ratios of 1:1 and 2:1. The 
characteristic diffraction peaks observed at 10.09°, 11.87°, 
13.53°, 16.34°, 26.09°, and 26.92° correspond to the pow-
der diffraction pattern for pure APM, while the absence 
of  diffraction peaks in the solid dispersions confirms 
their amorphous structure. The crystalline state of APM 
in the physical mixture of S244 and APM is evident from 
the characteristic diffraction peaks. The less intense dif-
fraction peaks in the MW solid dispersion at a ratio of 1:1 
indicates the partially crystalline state of APM deposited 
between the pore walls as a result of the blockage of pores 
with viscous molten APM. However, the XRPD pattern 
in the MW solid dispersion at a ratio of 2:1 suggests the 
amorphous structure of  APM within the formulation. 
It also confirms that the APM was confined within the 
pores of S244. These XRPD results are compatible with the 
DSC observations discussed above. S224 is a non-ordered 
porous silicon dioxide with a neutral pH and has randomly 
oriented pores with an average pore diameter of 19 nm.40 
The single-crystal structure of APM has been reported for 
its ethanol hemisolvate solvomorph.24 This single-crystal 
structure is most stable experimentally determined con-
formation of APM, and this conformation was therefore 
used to measure the size and shape of APM. Another rea-
son for using the single-crystal structure is that very small 
changes in the conformation of a molecule or changes in 
the hydrogen bonds around the molecule can have major 
effects on its size, shape, surface area and volume.
As shown in Fig.  4, the most widely spaced atoms in 
APM are 14.7 Å apart. The unit cell dimensions required 
to fit the conformer of APM are 1.29 × 1.29 × 1.47 nm, cal-
culated using Discovery Studio (Biovia, San Diego, USA) 
with the PyMOL interface (Schrödinger LLC, New York, 
USA). This suggests that the size of APM is below 1.9 nm, 
whereas the pore size of S244 is in the range of 19–20 nm. 
Therefore, the restricted pore size of S244 may have in-
hibited the crystallization of  APM inside the pores. 
In summary, the transformation of APM from crystalline 
to amorphous form is highly dependent on the selection 
of an optimum carrier/drug ratio and on the formulation 
method.
Fig. 3. X-ray powder diffraction (XRPD) patterns of solid dispersion  
(MW 2:1, MW 1:1), solid dispersion (CM 1:1), the physical mixture (PM)  
of S244and apremilast (APM), S244, and APM
Fig. 4. Representation of a 3-dimensional apremilast (APM) molecule with 
inter-atomic distances shown
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Surface morphology 
Scanning electron microscopy images of  APM, the 
physical mixture of  APM and S244 and the MW sol-
id dispersion of S244 and APM (2:1) are presented in 
Fig. 5. The SEM images of pure APM showed irregu-
larly shaped crystals of  the drug with large particles, 
showing its existence in the crystalline form. When 
APM was converted into solid dispersions, the mor-
phology changed to an amorphous state with a  fine 
particle size.
Preparation of apremilast tablets 
Based on the results of  our solubility studies, DSC 
thermograms and X-ray powder diffraction patterns, 
the best solid dispersion was found to be Batch 7 (MW 
2:1). This was used to prepare tablets. The post-com-
pression parameters of  the uncoated tablets are pre-
sented in Table 5.
Dissolution studies 
From the dissolution profiles, it is evident that the 
APM tablets prepared with the MW-assisted solid dis-
persion at a  2:1 ratio had a  significantly better APM 
dissolution rate as compared to the marketed formula-
tion (Aprezo tablets) (Fig. 6). Factors such as the lack 
of a crystalline form, the increased surface area of the 
drug, and the hydrophilic surface of S244 helped im-
prove the dissolution of APM. When this formulation 
comes into contact with the dissolution media, a rapid 
release of  APM in the form of  fine particles occurs, 
possibly because of  desorption of  APM by the influx 
of  the dissolution media inside the pores of  S244.28 
These results are in agreement with the findings 
of  earlier researchers,39 who used MW-induced solid 
dispersions to improve the solubility of APM.
Conclusions 
In summary, solid dispersions of APM, a poorly wa-
ter-soluble drug, with Syloid 244FP as a  carrier were 
prepared by CM and MW-assisted method. The latter 
was found to be a  suitable and less time-consuming 
method. The prepared solid dispersions were evalu-
ated for physicochemical parameters. The study shows 
that the dissolution rate of  APM can be improved 
using Syloid 244FP as a  carrier. The transformation 
of APM from crystalline to amorphous form is highly 
dependent on the selection of  an optimum carrier/
drug ratio and formulation method. The tablet formu-
lation of solid dispersion (Batch 7, MW 2:1) (S244 with 
APM, MW 2:1) showed a higher dissolution rate when 
compared with the reference tablets.
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